- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Advinus Therapeutics, a TATA Enterprise, Meets Milestone in Drug Discovery Alliance
PUNE: Advinus Therapeutics Ltd., the TATA promoted pharmaceutical R&D company, announced that it has reached the third milestone in its research and development collaboration with Takeda Pharmaceutical Company Limited. The achievement of this milestone highlights the success of the collaboration.
In October 2012, Advinus and Takeda announced a multi-year, multi-project collaboration in the area of drug discovery. In this collaboration, Advinus is responsible for carrying out all the research required to identify candidate molecules for clinical development in several therapeutic areas while Takeda is responsible for the development and commercialization of these candidates.
In each of the previous two years, Advinus has met predetermined milestones. The achievement of the third milestone underscores the rapid progress of the research programs over the past year, a result of the innovative solutions and the speed and quality of Advinus' efforts supported by Takeda's guidance and highly interactive engagement.
"The achievement of the third milestone by Advinus' young and talented scientists is a clear demonstration of how an effective partnership could deliver novel and effective candidates for drug development in a cost effective manner," said Kasim Mookhtiar, CEO & MD of Advinus.
In October 2012, Advinus and Takeda announced a multi-year, multi-project collaboration in the area of drug discovery. In this collaboration, Advinus is responsible for carrying out all the research required to identify candidate molecules for clinical development in several therapeutic areas while Takeda is responsible for the development and commercialization of these candidates.
In each of the previous two years, Advinus has met predetermined milestones. The achievement of the third milestone underscores the rapid progress of the research programs over the past year, a result of the innovative solutions and the speed and quality of Advinus' efforts supported by Takeda's guidance and highly interactive engagement.
"The achievement of the third milestone by Advinus' young and talented scientists is a clear demonstration of how an effective partnership could deliver novel and effective candidates for drug development in a cost effective manner," said Kasim Mookhtiar, CEO & MD of Advinus.
Next Story